Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Genmab AS (GMAB)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genmab AS's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
28.70 +0.37    +1.31%
16:00:01 - Closed. Currency in USD ( Disclaimer )
After Hours
28.70
-0.00
-0.00%
16:52:51 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 314,282
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 28.45 - 28.81
Genmab AS 28.70 +0.37 +1.31%

GMAB Income Statement

 
Featured here, the Income Statement (earnings report) for Genmab AS, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Revenue 4678 4744 4198 2854
Revenue 4678 4744 4198 2854
Other Revenue, Total - - - -
Cost of Revenue, Total 126 100 - -
Gross Profit 4552 4644 4198 2854
Total Operating Expenses 3008 3027 2701 2417
Selling/General/Admin. Expenses, Total 934 839 848 676
Research & Development 1948 2088 1853 1741
Depreciation / Amortization 185 - - -
Interest Expense (Income) - Net Operating -6 -8 -7 -6
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -179 8 7 6
Operating Income 1670 1717 1497 437
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets 131 36 34 92
Other, Net 613 -1021 -260 59
Net Income Before Taxes 926 2702 1723 286
Provision for Income Taxes 286 573 366 60
Net Income After Taxes 640 2129 1357 226
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 640 2129 1357 226
Total Extraordinary Items - - - -
Net Income 640 2129 1357 226
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 640 2129 1357 226
Dilution Adjustment 0.311 - - -
Diluted Net Income 639.69 2129 1357 226
Diluted Weighted Average Shares 66.04 65.87 65.84 65.89
Diluted EPS Excluding Extraordinary Items 9.69 32.32 20.61 3.43
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS 7.52 25.3 16.03 1.84
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GMAB Comments

Write your thoughts about Genmab AS
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
David Klepetko
klepid Nov 10, 2021 11:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ERs are out https://ir.genmab.com/financial-calendar
Reply
0 0
Report
Jens Jensen
Jens Jensen Aug 11, 2021 3:39PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
And no debt, $3B cash position, one of the most "trending" technologies around (bispecific antibodies) and an impressive outflux of new drugs via seemingly peerpoor (now that's a nice new word - you're free to use it;-) quality of research. I urge everyone to check it out - heres the Investor Presentation for Q22021 "https://ir.genmab.com/static-files/cac2e584-6554-4637-a367-a5d21abc51e0". Comp value 2day $30B, best realistic ;-) guess is double up in 3-4 yrs. Seriously.
Reply
0 0
Report
Jens Jensen
Jens Jensen Aug 11, 2021 3:14PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Falling.. standard market reaction these days to good and solid reportings: crazy that is.. in spite of improved revenue outlook, 4 drugs on market (darazalex(need I say more?)+3 soon-to-become-blockbusters) + 1 prob-to-market-in-october (tisotumab vedotin, w Seagen) + 2 new drugs revealed (one of which: inclacumab - a Sickle Cell Disease treatment, outlicensed to Roche and further outlicensed to Global Blood Therapeutics, but none the less - w potential for BB).
Reply
0 0
Report
BumHunters Archer
JohnJenga Mar 10, 2021 8:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
32, 40 again soon
Reply
0 0
Report
Morten Lyng
Morten Lyng May 28, 2020 4:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Luxus
Reply
0 0
Report
Morten Lyng
Morten Lyng May 26, 2020 6:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Going 200 % up in the next 24-30 month
Reply
4 0
Report
Mirko Prazzoli
Mirko Prazzoli May 12, 2020 12:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what about this stock?
Reply
0 0
Report
Morten Lyng
Morten Lyng May 02, 2020 3:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The best upcoming medico company for cancer
Reply
4 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email